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he Aurora/Ipl1 family of protein kinases plays multiple
roles in mitosis and cytokinesis. Here, we describe
ZM447439, a novel selective Aurora kinase inhibitor.
Cells treated with ZM447439 progress through interphase,
enter mitosis normally, and assemble bipolar spindles. How-
ever, chromosome alignment, segregation, and cytokinesis
all fail. Despite the presence of maloriented chromosomes,
ZM447439-treated cells exit mitosis with normal kinetics,
indicating that the spindle checkpoint is compromised.
Indeed, ZM447439 prevents mitotic arrest after exposure to
paclitaxel. RNA interference experiments suggest that these
phenotypes are due to inhibition of Aurora B, not Aurora A
T
 
or some other kinase. In the absence of Aurora B function,
kinetochore localization of the spindle checkpoint compo-
nents BubR1, Mad2, and Cenp-E is diminished. Furthermore,
inhibition of Aurora B kinase activity prevents the rebinding
of BubR1 to metaphase kinetochores after a reduction in
centromeric tension. Aurora B kinase activity is also required
for phosphorylation of BubR1 on entry into mitosis. Finally,
we show that BubR1 is not only required for spindle check-
point function, but is also required for chromosome align-
ment. Together, these results suggest that by targeting
checkpoint proteins to kinetochores, Aurora B couples
chromosome alignment with anaphase onset.
 
Introduction
 
Accurate chromosome segregation in mitosis requires that
sister kinetochores attach to microtubules emanating from
opposite spindle poles. Because kinetochore attachment is a
stochastic process, it is error prone and can result in chromo-
some malorientation (Nicklas, 1997; Rieder and Salmon,
1998). Although it is well established that a surveillance
mechanism, the spindle checkpoint, delays anaphase until all
chromosomes correctly bi-orient (for review see Musacchio
and Hardwick, 2002), the mechanisms that detect and resolve
orientation errors are poorly understood.
The Ipl1/Aurora family of protein kinases plays multiple
roles in mitosis (Bischoff and Plowman, 1999; Giet and
Prigent, 1999; Adams et al., 2001a; Nigg, 2001). In budding
yeast, Ipl1 ensures accurate chromosome segregation by resolv-
ing syntelic orientations, possibly by monitoring tension at
centromeres and destabilizing inappropriately bound micro-
tubules (Tanaka et al., 2002). Ipl1 phosphorylates the ki-
netochore component Ndc10 in vitro, suggesting that it
may regulate kinetochore–microtubule interactions directly
(Biggins et al., 1999). However, budding yeast are atypical
in that centromeres connect to the unduplicated spindle
pole body (SPB) in G1. Because centromeres replicate before
SPB duplication, budding yeast cells then enter mitosis with
both kinetochores attached to the old SPB (Tanaka et al.,
2002). In higher eukaryotes, syntelic orientations are rare
during mitosis (Nicklas, 1997), and therefore, it is unclear
whether the kinetochore–SPB resolving activity exhibited by
Ipl1 is a universal feature of the Aurora kinase family. Further
evidence suggesting that Ipl1 monitors tension at centromeres
comes from analyzing budding yeast mutants that lack sister
chromatid cohesion or enter mitosis without replicating
their DNA. In such mutants, anaphase is prevented in an
Ipl1-dependent manner (Biggins and Murray, 2001). Because
kinetochores in these cells lack sisters, they fail to come under
tension despite microtubule attachment, arguing that Ipl1 is
required for spindle checkpoint activation in response to loss
of tension at centromeres. However, budding yeast kineto-
chores only attach a single microtubule. Therefore, if the
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primary role of Ipl1 is to destabilize bound microtubules,
the apparent role of Ipl1 in checkpoint activation may be
simply a secondary consequence of exposing microtubule
binding sites (Tanaka et al., 2002). Furthermore, although
the analysis of replication and cohesion mutants suggests
that Ipl1 monitors tension at centromeres, these interpreta-
tions are complicated by the fact that centromeric localiza-
tion of the fission yeast Aurora kinase, Ark1, requires sister
chromatid cohesion (Morishita et al., 2001). Therefore,
there is a clear need to analyze Aurora kinase function under
conditions where replication and cohesion are normal.
Higher eukaryotes express two or more Aurora kinases.
Aurora A and C localize to spindle poles, and Aurora A is re-
quired for bipolar spindle formation in a variety of systems
(Bischoff and Plowman, 1999; Giet and Prigent, 1999; Ad-
ams et al., 2001a; Nigg, 2001). Inhibition of Aurora B, an
inner centromere protein, affects multiple mitotic events in-
cluding histone H3 phosphorylation, chromosome segrega-
tion, and cytokinesis (Bischoff and Plowman, 1999; Giet
and Prigent, 1999; Adams et al., 2001a; Nigg, 2001). The
role of Aurora B kinase activity has been addressed by ectop-
ically expressing mutants in mammalian cells. However,
these studies have yielded conflicting results. In two cases,
cells expressing Aurora B K109R completed mitosis, but
failed to undergo cytokinesis, suggesting that Aurora B activ-
ity is not required for chromosome segregation (Tatsuka et
al., 1998; Terada et al., 1998). However, another report in-
dicates that Aurora B K109R prevents chromosome align-
ment due to the failure of kinetochore–microtubule interac-
tions (Murata-Hori and Wang, 2002). These experiments
are complicated by the fact that expression of wild-type Au-
rora B can itself affect cell division (Tatsuka et al., 1998),
and therefore, it is not clear whether these phenotypes are
due to reduced Aurora B kinase activity or the disruption of
Aurora B protein complexes. 
 
Xenopus
 
 cells injected with
anti-Aurora B antibodies exit mitosis prematurely, consis-
tent with a role for Aurora B in the spindle checkpoint (Kal-
lio et al., 2002). However, in contrast to Ipl1 deficient
strains, mitotic exit also occurred when microtubule poly-
merization was inhibited, suggesting that Aurora B monitors
microtubule attachment, not just tension. Thus, although
many roles have been attributed to Aurora B, the emerging
picture is confusing, and molecular explanations for these
phenotypes are currently lacking.
Aurora A and B are overexpressed in human tumors, and
ectopic overexpression in cultured cells leads to transforma-
tion, centrosome abnormalities, and aneuploidy (Bischoff et
al., 1998; Tatsuka et al., 1998; Zhou et al., 1998; Adams et
al., 2001b; Meraldi et al., 2002). In addition, cells overex-
pressing Aurora A, but not a kinase mutant, readily form tu-
mors in nude mice (Bischoff et al., 1998). Therefore, ele-
vated Aurora kinase activity may promote tumor evolution
either by providing a growth advantage or by promoting ge-
netic instability. To develop novel anti-cancer drugs, we
have generated small molecule inhibitors of Aurora kinase
activity. Here, we describe ZM447439, which selectively
inhibits the kinase activity of Aurora A and B. Using
ZM447439 as a research tool, we directly address the role of
Aurora kinase activity in human cells. We show that inhibi-
tion of Aurora kinase activity does not prevent progression
 
through interphase, mitotic entry, bipolar spindle forma-
tion, or kinetochore–microtubule interactions. Rather, Au-
rora kinase activity is required for correct chromosome
alignment and spindle checkpoint function. Using RNA in-
terference (RNAi;* Elbashir et al., 2001), we demonstrate
that these phenotypes are due to inhibition of Aurora B, not
Aurora A.
 
Results
 
ZM447439, a novel inhibitor of Aurora A and Aurora B
 
To identify novel Aurora inhibitors, 
 
 
 
250,000 compounds
were screened for the ability to inhibit the kinase activity of
recombinant human Aurora A against an artificial peptide
substrate. One inhibitor identified was further modified to
produce ZM447439 (4-(4-(
 
N
 
-benzoylamino)anilino)-6-
methoxy-7-(3-(1-morpholino)propoxy)quinazoline; Fig. 1
A). In in vitro kinase assays using purified recombinant pro-
teins, ZM447439 inhibited Aurora A and B with IC
 
50
 
 val-
ues of 110 and 130 nM, respectively (Fig. 1 B). In contrast,
the majority of other protein kinases assayed were not in-
hibited by ZM447439. Based on data from model systems,
we predicted that an Aurora inhibitor should prevent cell
division and inhibit phosphorylation of histone H3 on
serine 10. To determine whether ZM447439 inhibits cell
division, a panel of human cell lines was treated with 2 
 
 
 
M
ZM447439 for up to 96 h (Fig. 1 C). After 18 h, the vast
majority of cells in all the lines had 4N DNA contents. All
the lines analyzed then endoreduplicated, accumulating
cells with DNA contents greater than 4N, demonstrating
that ZM447439 completely inhibits cell division. To deter-
mine whether ZM447439 inhibits phosphorylation of his-
tone H3 on serine 10, untreated and ZM447439-treated
cells were stained with an anti-phosphohistone H3 anti-
body (Hsu et al., 2000). In untreated cells, chromosomes
stained positive for phosphohistone H3 (Fig. 1 D). How-
ever, after brief exposures to ZM447439, phosphohistone
H3 was not detectable, demonstrating that ZM447439
does inhibit mitotic phosphorylation of histone H3. Con-
sistent with previous observations (Adams et al., 2001c),
the lack of histone H3 phosphorylation did not appear to
affect chromosome condensation.
 
ZM447439-induced endoreduplication is enhanced 
in the absence of p53 function
 
Although a significant fraction of A549 and HME cells en-
doreduplicated in the presence of ZM447439, after 48 h vir-
tually all the cells arrested with either 4N or 8N DNA con-
tents (Fig. 1 C). In contrast, HeLa cells, which lack a
functional p53 response, continued DNA synthesis and rap-
idly lost viability. This raises the possibility that the 4N/8N
arrest exhibited by the A549 and HME cells was not directly
due to ZM447439, but was rather due to activation of the
p53-dependent post-mitotic checkpoint that occurs after an
aberrant mitosis and/or cytokinesis (Andreassen et al.,
2001). Consistently, in the presence of ZM447439, U2OS
cells expressing a dominant-negative p53 mutant endoredu-
 
*Abbreviation used in this paper: RNAi, RNA interference.T
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plicated efficiently such that by 48 h, 78% had 8N DNA
contents (Fig. 2 A). In contrast, only 38% of the p53-profi-
cient parental U2OS cells had 8N DNA contents, demon-
strating that p53 does restrain cell cycle progression after
ZM447439-induced division failure. To test if cell cycle
progression in the presence of ZM447439 may account
for why the HeLa cells lost viability, we analyzed the col-
ony-forming potential of cells after a 72-h exposure to
ZM447439. MCF7 cells were selected for this experiment,
as they can be arrested in G0 by treatment with anti-estro-
gens. Cells that were growth-arrested during exposure to
ZM447439 gave rise to more colonies than those that were
proliferating (Fig. 2 B). Consistently, at 1.25 and 2.5 
 
 
 
M
ZM447439, the cloning efficiency of the proliferating cells
was reduced to below 40%, whereas the cloning efficiency of
the growth-arrested cells was largely unaffected (Fig. 2 C).
Although continued cell cycle progression in the presence of
ZM447439 leads to loss of viability, the p53-deficient
Figure 1. ZM447439 inhibits Aurora A and Aurora B. (A) Chemical structure of ZM447439. (B) Table showing the IC50 values ( M) of 
ZM447439 against a panel of protein kinases. (C) DNA content histograms of HeLa, A549, and HME cells treated with ZM447439 for the 
times indicated in hours. (D) Mitotic DLD-1 cells stained for phosphohistone H3 (green) and DNA (red).T
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U2OS cells did not appear to lose viability as rapidly as the
HeLa cells. The reason for this is unclear, but it suggests that
p53-independent mechanisms may also affect cell fate after
ZM447439-induced tetraploidization.
 
ZM447439-treated cells enter mitosis, but fail to divide
 
The observation that ZM447439-treated cells can enter ad-
ditional S phases without dividing raises two possibilities: ei-
ther the cells re-replicate their genomes without entering mi-
tosis, or alternatively, the cells enter and exit mitosis without
dividing and then enter a second S phase. To distinguish be-
tween these two possibilities, we analyzed HeLa cells after
release from a G1/S block into fresh medium or media sup-
plemented with either ZM447439 or nocodazole, a spindle
toxin that prevents microtubule polymerization (Fig. 3). At
various times after G1/S, the cells were harvested to deter-
mine DNA content, mitotic index, and cyclin B1 levels.
DNA content histograms show that the vast majority of
control cells divided by 12 h then entered a second S phase
such that by 18 h, the majority had DNA contents greater
than 2N (Fig. 3 A). Consistently, the mitotic index peaked
at 10 h and cyclin B1 levels decreased as the cells completed
mitosis (Fig. 3, B and C). Nocodazole-treated cells entered
mitosis, and then remained arrested with high cyclin B1 lev-
els for the remainder of the experiment. Cells released into
ZM447439 progressed through S phase, failed to divide, de-
graded cyclin B1 normally, and then entered a second S
phase (Fig. 3, A and C). Significantly, the kinetics with
which the mitotic index increased and decreased was very
similar to the control culture (Fig. 3 B). Thus, in the pres-
ence of ZM447439, HeLa cells enter and exit mitosis nor-
mally, but fail to divide. A549 and HME cells exhibited a
similar response (unpublished data).
 
ZM447439 inhibits chromosome alignment
 
The observation that ZM447439-treated cells enter and exit
mitosis but fail to divide raises two possibilities: either chro-
mosome segregation takes place normally but cytokinesis
fails, or alternatively, chromosome segregation fails, prevent-
ing cytokinesis. To determine whether ZM447439 prevents
chromosome segregation, we analyzed spindle morphology
in ZM447439-treated cultures. In controls, prometaphase
rosettes, and metaphase and anaphase spindles were readily
apparent (Fig. 4, A and B). In ZM447439-treated cultures,
bipolar spindles were observed and the proportion of cells in
prophase appeared normal. However, the proportion of
metaphase and anaphase spindles was markedly reduced, in-
dicating that ZM447439 inhibits chromosome segregation
(Fig. 4 B). Despite the lack of anaphases, cells treated with
ZM447439 alone did not accumulate in mitosis (Fig. 4 C).
Cells treated with ZM447439 and nocodazole did however
accumulate in mitosis, confirming that ZM447439-treated
cells enter and exit mitosis without undergoing chromosome
segregation. Chromosome alignment also appeared abnor-
mal in the presence of ZM447439. In particular, the chro-
mosomes either splayed out throughout the cell or, rather
than aligning at the spindle equator, lined up along the
length of the spindle (Fig. 4 A). In these latter cases, the ki-
netochores were oriented toward the spindle, suggesting that
kinetochore–microtubule interactions were taking place. In-
deed, kinetochores and kinetochore fibers were observed in
thin sections analyzed by electron microscopy (Fig. 4 D). In
19 control cells, fibers containing multiple microtubules
were observed in 12 cases. Eight of these could be traced to
Figure 2. p53 restrains endoreduplication in the presence of 
ZM447439. (A) DNA content histograms of U20S cells with (p53 ) 
or without (p53 ) a functional p53 response treated with ZM447439 
for the times indicated in hours. (B) Growth-arrested or proliferating 
MCF-7 cells were exposed to ZM447439 for 72 h, and were then 
assayed for the ability to form colonies in the absence of ZM447439. 
(C) Bar graph quantitating the cloning efficiency of MCF-7 cells 
treated with a range of ZM447439 concentrations. Each value 
represents the mean and SD from three independent experiments.T
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kinetochores. In 20 ZM447439-treated cells, fibers contain-
ing multiple microtubules were observed in 15 cases, and six
were traced to kinetochores. Although we cannot rule out
the possibility that ZM447439 effects kinetochore structure
and/or microtubule binding capacity, ZM447439 clearly
does not prevent kinetochore–microtubule interactions or
bipolar spindle formation. However, ZM447439 does in-
hibit chromosome alignment and segregation. To determine
whether ZM447439 prevents sister chromatid separation,
we allowed cells to pass through mitosis in the presence of
ZM447439, and then analyzed chromosome spreads in the
following mitosis. Diplochromosomes were never observed
(unpublished data), suggesting that ZM447439 does not
prevent loss of sister chromatid cohesion. It is unclear
whether ZM447439 directly inhibits cytokinesis or whether
cytokinesis is prevented as a secondary consequence of the
block to chromosome segregation.
 
ZM447439 compromises spindle checkpoint function
 
The observations described above present a paradox:
chromosome alignment defects should activate the spin-
dle checkpoint, and thus cause mitotic arrest. However,
ZM447439-treated cells exit mitosis with normal kinetics
(Fig. 3 B), suggesting that ZM447439 may compromise
checkpoint function. To test this possibility, we analyzed the
effect of ZM447439 on cells after release from a nocodazole
block. Nocodazole-arrested mitotic cells were isolated by se-
lective detachment, washed to remove the nocodazole, and
were then replated in various drug combinations (Fig. 5,
A–C). At various times the cells were harvested to determine
DNA content, mitotic index, and cyclin B1 levels. 2 h after
release, the majority of the control cells had completed chro-
mosome segregation and divided (Fig. 5 A). In contrast,
ZM447439, nocodazole, and ZM447439 plus nocodazole-
treated cells failed to divide (unpublished data). The mitotic
index of the control cells was initially high, but then fell to
15% 2 h after release. In contrast, in the continued presence
of nocodazole the cells remained arrested in mitosis (Fig. 5
B). Consistently, in control cells, cyclin B1 levels fell after
2 h but remained high in the presence of nocodazole (Fig. 5
C). Strikingly, the mitotic index of ZM447439-treated cells
fell extremely rapidly: after 1 h, only 4% of the ZM447439-
treated cells were still in mitosis, compared with 67% of the
controls (Fig. 5 B). Consistently, cyclin B1 was undetectable
after 1 h. Thus, ZM447439-treated cells rapidly exit mitosis,
consistent with the notion that ZM447439 overrides the
spindle checkpoint.
However, asynchronous cultures treated with ZM447439
and nocodazole accumulated cells in mitosis (Fig. 4 C), indi-
cating that ZM447439 does not override the checkpoint un-
der all circumstances. To explain this, we reasoned that per-
haps ZM447439 only compromises the checkpoint when
Figure 3. ZM447439-treated cells enter mitosis, but fail to divide. HeLa cells were released from G1/S into various drug combinations, 
harvested at the times indicated in hours, and then analyzed by flow cytometry and immunoblotting. The data shown are representative of 
three independent experiments. The data in A and B are from the same experiment where the mitotic index peaked 10 h after release from 
G1/S. The data in C are from an independent experiment where the mitotic index peaked 12 h after release from G1/S. (A) DNA content 
histograms showing that ZM447439-treated cells fail to divide, but re-replicate their genomes with similar kinetics to the control cells. 
(B) Graph plotting mitotic index, as determined by MPM-2 reactivity, against time showing that ZM447439-treated cells enter and exit mitosis 
with similar kinetics to the controls. (C) Immunoblots showing that cyclin B1 levels rise and fall in ZM447439-treated cells with similar kinetics 
to the controls. Tubulin is used as a loading control.T
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microtubules are allowed to polymerize. To test this, we an-
alyzed the effect of ZM447439 on the accumulation of mi-
totic cells in response to paclitaxel, a spindle toxin that
activates the checkpoint by stabilizing microtubules. In
the presence of paclitaxel, nocodazole, or nocodazole plus
ZM447439, the mitotic index reached 
 
 
 
25% after 6 h (Fig.
5 D). In contrast, the mitotic index of the ZM447439-
treated culture remained low at 
 
 
 
7%. Significantly, the mi-
totic index of the culture treated with paclitaxel plus
ZM447439 reached only 12%. To confirm this differential
effect, we determined the mitotic index of nocodazole- and
paclitaxel-treated cultures over a range of ZM447439 con-
centrations. Fig. 5 E clearly shows that ZM447439 resolves
the pharmacological effects nocodazole and paclitaxel have
on checkpoint function. Thus, these observations confirm
that ZM447439 can efficiently override the spindle check-
point when microtubules are allowed to polymerize.
Although asynchronous cultures treated with ZM447439
and nocodazole accumulate mitotic cells in a manner similar
to cultures treated with nocodazole alone (Fig. 4 C), after a
12-h nocodazole block, mitotic cells released into nocodazole
plus ZM447439 exit mitosis faster than cells released into
nocodazole alone (Fig. 5 B). This suggests that perhaps after
prolonged mitotic arrest, ZM447439 can also compromise
Figure 4. ZM447439 prevents chromosome alignment and segregation. (A) Mitotic DLD-1 cells stained for tubulin, kinetochores/centromeres 
(ACA, green), and DNA (red). Bottom panels show examples of abnormal prometaphases frequently observed after treatment with ZM447439 
for 1 h. (B) Graph quantitating the number of prophase (P), prometaphase (PM), metaphase (M), and anaphase (A) cells after exposure of 
DLD-1 cells to ZM447439 for 1 h, showing that chromosome alignment and segregation are inhibited. (C) Graph showing the mitotic index 
of DLD-1 cultures at the times indicated after treatment with either ZM447439 alone (red diamonds), nocodazole (yellow squares), or 
ZM447439 plus nocodazole (blue triangles). Values in B and C represent the mean and SEM derived from three independent experiments 
in which at least 1,000 cells were counted. (D) Electron micrographs of ZM447439-treated HeLa cells showing kinetochores (arrows) and 
kinetochore fibers.T
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the checkpoint induced by microtubule depolymerization.
To test this, mitotic HeLa cells were harvested after a 2- or
12-h nocodazole block, then replated for 4 h in either no-
codazole alone or nocodazole plus ZM447439. Although
 
 
 
80% of the cells harvested after a 2-h block remained ar-
rested in the presence of ZM447439 and nocodazole, only
 
 
 
20% of the cells isolated after a 12-h block remained ar-
rested. Thus, after prolonged mitotic arrest, ZM447439 can
compromise checkpoint arrest induced by microtubule depo-
lymerization. However, what is clearly evident from this anal-
ysis is that in the short term, ZM447439-treated cells do un-
dergo mitotic arrest when microtubules are depolymerized,
but fail to arrest when microtubules are stabilized (Fig. 5 E).
 
ZM447439 inhibits kinetochore localization of BubR1, 
Mad2, and Cenp-E
 
To gain insight into how ZM447439 compromises chro-
mosome alignment and checkpoint function, we analyzed
 
its effect on the localization of Aurora A, Aurora B, Sur-
vivin, the spindle checkpoint components BubR1 and
Mad2, and the kinesin-related motor protein Cenp-E.
ZM447439 did not prevent localization of Aurora A to
spindle poles (unpublished data) or the localization of
Aurora B and Survivin to centromeres (Fig. 6 A). How-
ever, ZM447439 did reduce kinetochore bound BubR1,
Cenp-E, and Mad2 (Fig. 7 A and Fig. S1, available at
http://www.jcb.org/cgi/content/full/jcb.200208091/DC1).
Quantitation of pixel intensities shows that ZM447439 re-
duced kinetochore-associated BubR1 to 
 
 
 
10%, both in the
presence and absence of microtubule toxins (Fig. 7 B, Fig.
S1, and Table SI). ZM447439 reduced kinetochore-bound
Mad2 to 
 
 
 
10% in prometaphase cells and to 30 and 43%
in the presence of nocodazole and paclitaxel, respectively
(Fig. S1 C). Kinetochore-bound Cenp-E was reduced to 28
and 23% in cells treated with ZM447439 and ZM447439
plus paclitaxel, respectively. However, in the presence of
Figure 5. ZM447439 compromises spindle checkpoint function. (A–C) Mitotic HeLa cells were isolated by selective detachment after a 
12-h nocodazole block, replated in various drugs combinations, and then harvested at the times indicated in hours and analyzed. (A) DNA 
content histograms showing that the control cells divide after 1 h. (B) Graph plotting the mitotic index, as determined by MPM-2 reactivity, 
showing that ZM447439 accelerates mitotic exit. (C) Immunoblots showing that cyclin B1 and phosphohistone H3 levels fall rapidly in 
ZM447439-treated cells. (D and E) DLD-1 cells were treated with drug combinations and were then fixed and analyzed by fluorescence 
microscopy. (D) Bar graph plotting the mitotic index after 6 h, showing that ZM447439 compromises paclitaxel- but not nocodazole-induced 
mitotic arrest. (E) Line graph plotting the mitotic index after 8 h, showing that ZM447439 resolves the effects of nocodazole and paclitaxel 
with respect to spindle checkpoint function. Values in D and E represent the mean and SEM derived from three independent experiments in 
which at least 1,000 cells were counted. Drug combinations used were nocodazole alone (Noc, yellow squares); paclitaxel alone (Tax); 
ZM447439 alone (ZM, red diamonds); nocodazole plus ZM447439 (NZ, blue triangles); paclitaxel plus ZM447439 (TZ, green squares); and 
no drug (Control, green circles). (F) Mitotic HeLa cells harvested after a 2- or 12-h nocodazole block were replated in nocodazole (black bar) 
or nocodazole plus ZM447439 (white bars), and the mitotic index was determined by measuring MPM-2 reactivity after 4 h. Bar graph shows 
that ZM447439 compromises nocodazole-induced checkpoint activation after prolonged mitotic arrest.T
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nocodazole and ZM447439, Cenp-E was only reduced to
59%. Interestingly, inspection of the fluorescence intensity
histograms (Fig. S2) shows that in the presence of noco-
dazole, although ZM447439 reduced kinetochore-bound
Cenp-E at the majority of kinetochores, a significant num-
ber retained normal Cenp-E levels (30% have a Cenp-E/
ACA ratio greater than the mean value for kinetochores
in cells treated with nocodazole only). In contrast, no ki-
netochores had normal BubR1 levels in the presence of
ZM447439 and nocodazole (0% have a BubR1/ACA ratio
greater than the mean nocodazole only value).
 
Although kinetochore-bound BubR1 diminishes after
chromosome alignment (Chan et al., 1999; Taylor et al.,
2001), it is recruited back to metaphase kinetochores after
the loss of tension induced by low levels of vinblastine
(Skoufias et al., 2001). To determine whether ZM447439 in-
hibits the reassociation of BubR1 with aligned kinetochores
after loss of tension, we measured BubR1 signal intensity
and interkinetochore distance at metaphase kinetochores af-
ter a 40-min treatment with either ZM447439 or paclitaxel
(Fig. 7 C and Table SII). After paclitaxel treatment, the
mean interkinetochore distance was reduced from 0.89 
 
 
 
0.20 
 
 
 
m to 0.58 
 
 
 
 0.15 
 
 
 
m (P 
 
 
 
 0.001), and the mean
BubR1/ACA fluorescence ratio increased from 2.23 
 
 
 
 1.21
to 3.86 
 
 
 
 2.41 (P 
 
 
 
 0.001). In contrast, although exposure to
ZM447439 reduced the mean interkinetochore distance to
0.55 
 
 
 
 0.14 
 
 
 
m, the BubR1/ACA fluorescence ratio de-
creased to 1.11 
 
 
 
 0 0.88 
 
 
 
m, which is statistically different
from the paclitaxel-treated and control cells (P 
 
 
 
 0.001).
BubR1 is phosphorylated in response to spindle damage
(Chan et al., 1999; Taylor et al., 2001). To determine
whether ZM447439 prevents BubR1 phosphorylation, mi-
totic cells were harvested 
 
 
 
9.5 h after release from a G1/S
block into various drug combinations. In the presence of
ZM447439, the phosphorylated form of BubR1 was not de-
tectable, either in the presence or absence of nocodazole
(Fig. 7 D). To rule out the possibility that ZM447439 in-
hibits BubR1 directly, BubR1 immunoprecipitates were as-
sayed for kinase activity in the presence and absence of
ZM447439. Although ZM447439 inhibited Aurora A, it
did not inhibit BubR1 (Fig. 7 E).
 
Repression of Aurora B inhibits kinetochore 
localization of BubR1, Cenp-E, and Mad2
 
The ZM447439 data suggest that Aurora kinase activity
is required for chromosome alignment and spindle check-
point function. To determine which Aurora is required for
these functions, and to rule out the possibility that the
ZM447439 phenotypes might be due to inhibition of an-
other kinase, we repressed Aurora A and B by RNAi (Fig. 8
A). Although control and Aurora A RNAi cultures had ro-
bust spindle checkpoints, repression of Aurora B reduced the
accumulation of mitotic cells after spindle damage (Fig. 8
B). Repression of Aurora B (but not Aurora A) inhibited ki-
netochore localization of BubR1, Cenp-E, and Mad2 (Fig. 8
C and Fig. S3). Thus, these observations indicate that the
ZM447439-induced phenotypes described above are due to
inhibition of Aurora B, not Aurora A or some other kinase.
 
Overexpression of Aurora B K106R mislocalizes 
the endogenous protein
 
The Aurora B RNAi phenotypes appear more severe than
those induced by ZM447439. In particular, Aurora B
RNAi compromised checkpoint arrest in response to no-
codazole as well as paclitaxel (Fig. 8 B). Furthermore, the
chromosomes were frequently adjacent to the spindle (Fig.
8 D), suggesting the absence of kinetochore–microtubule
interactions. Accordingly, the mean interkinetochore dis-
tance was markedly reduced (Fig. 8 E). One possible expla-
nation for these differences is that in addition to its catalytic
Figure 6. ZM447439 does not prevent localization of Aurora B to 
centromeres. Immunofluorescence images of prometaphase DLD-1 
cells stained to detect Aurora B (green), Survivin (red), and DNA 
(blue) after (A) exposure to ZM447439 for 1 h or (B) transfection 
of Aurora B siRNA duplexes. (C) Transiently transfected HeLa cells 
expressing either Myc-tagged Aurora B or Myc-tagged Aurora B 
K106R stained to detect Aurora B (green), Myc-tagged proteins 
(red), and DNA (blue).T
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role, Aurora B may also play a structural role at cen-
tromeres. Significantly, Aurora B, INCENP, and Survivin
form a complex that is required for multiple aspects of mi-
tosis and cytokinesis (Adams et al., 2001a). Disruption of
this complex may have more extensive consequences rather
than simply inhibiting Aurora B kinase activity. Consis-
tently, although Survivin localizes to centromeres after
ZM447439 treatment (Fig. 6 A), it does not after Aurora B
RNAi (Fig. 6 B). If the above argument is valid, ectopic ex-
pression of an Aurora B kinase mutant should produce a
phenotype similar to ZM447439. However, overexpression
of Aurora B K109R abolished kinetochore–microtubule in-
teractions (Murata-Hori and Wang, 2002), resulting in a
phenotype that is more consistent with our RNAi data.
Therefore, we tested whether Aurora B localized to cen-
tromeres after overexpression of the Aurora B kinase mu-
tant. After transient transfections of HeLa cells, the ex-
ogenous wild-type Aurora B localized to centromeres in
prometaphase (Fig. 6 C) and midbodies after cell division
(unpublished data). In addition, at low levels of expression,
the Aurora B K106R mutant also localized to centromeres
(note that human Aurora B K106R mutant is equivalent to
rat K109R mutant described previously in Murata-Hori
and Wang [2002]). However, in prometaphase cells ex-
pressing moderate to high levels of the K106R mutant, Au-
rora B was not apparent at centromeres (Fig. 6 C). Thus, in
contrast to treatment with the Aurora kinase inhibitor,
overexpression of an Aurora B kinase mutant prevents local-
ization of the endogenous protein to centromeres.
 
BubR1 is required for chromosome alignment
 
Our observations are consistent with the notion that Au-
rora B kinase activity regulates the spindle checkpoint, at
least in part, by targeting BubR1 to kinetochores. Because
BubR1 binds Cenp-E (Chan et al., 1999; Yao et al., 2000),
we reasoned that the requirement for Aurora B in promot-
ing correct chromosome alignment might also be mediated,
at least in part, via its affect on BubR1. To test this, we
used RNAi to determine whether repression of BubR1 in-
hibited chromosome alignment. Consistent with antibody
injection experiments (Chan et al., 1999), repression of
BubR1 compromised spindle checkpoint function. In
particular, in asynchronous cultures, the number of meta-
phases was reduced and the anaphases frequently displayed
lagging chromosomes (Fig. S4). Furthermore, BubR1
RNAi cultures did not accumulate mitotic cells on ex-
posure to spindle toxins (unpublished data). Strikingly,
prometaphase cells in BubR1 RNAi cultures often ap-
peared abnormal with the chromosomes aligned along the
length of the spindle rather than at the metaphase plate
(Fig. 9 A). Although these chromosomes appear to be at-
tached to the spindle, the mean interkinetochore distance
Figure 7. ZM447439 inhibits kinetochore localization and phosphorylation of BubR1. (A) Projections of deconvolved image stacks showing 
mitotic DLD-1 cells treated for 1 h with the drugs indicated and then stained to detect kinetochores/centromeres (ACA), BubR1, and DNA. 
(B) Bar graph plotting the fluorescence ratio of BubR1 to ACA signal under various conditions, showing that ZM447439 reduces the BubR1 
signal by  10-fold. Values represent the mean and SEM of at least 26 different kinetochore/centromere pairs analyzed in at least three 
different cells. (C) Plot of BubR1 signal intensity versus interkinetochore distance at metaphase kinetochores in untreated cells (green circles) 
or cells exposed to ZM447439 (red diamonds) or paclitaxel (blue squares) for 40 min. ACA foci were used to determine kinetochore position. 
The ovals encompass at least 75% of the data points. (D) Mitotic HeLa cells collected by selective detachment after release from G1/S into 
the drugs indicated were analyzed by immunoblotting. In the presence of ZM447439, the phosphorylated form of BubR1 is not detectable. 
(E) BubR1 was affinity purified form nocodazole-arrested mitotic HeLa cells and assayed for kinase activity in the presence ZM447439. Each 
value represents the mean and SEM derived from three independent experiments.T
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was reduced compared with control cells (Fig. 9 B), consis-
tent with a reduction in pulling forces.
To rule out the possibility that this alignment defect was
simply due to the cells prematurely entering anaphase, we
treated control and BubR1 RNAi cultures with the proteo-
some inhibitor MG132 to prevent anaphase onset. Over a
3-h time course, the number of prophases and anaphases fell to
almost zero in both control and BubR1 RNAi cultures (Fig.
S4). In control cultures, the proportion of prometaphases re-
mained roughly constant at 
 
 
 
25% and the proportion of
metaphases rose to 
 
 
 
66% (Fig. 9 C), consistent with
MG132 preventing the metaphase–anaphase transition.
However, in BubR1-repressed cultures, the proportion of
prometaphases rose from 
 
 
 
32 to 
 
 
 
49%, and the number of
metaphases reached only 
 
 
 
44% (Fig. 9 B). Thus, when the
metaphase–anaphase transition is blocked downstream of
spindle checkpoint activation, repression of BubR1 reduces
the accumulation of cells in metaphase, suggesting that
BubR1 is indeed required for chromosome alignment.
 
Discussion
 
ZM447439 is a novel specific inhibitor of Aurora 
kinase activity
 
The usefulness of protein kinase inhibitors as therapeutic
agents and experimental research tools depends on the selec-
tivity of the inhibitor. ZM447439 inhibits Aurora A and B
in vitro with IC
 
50
 
 values in the 100 nM range. In contrast,
when tested against a panel of 14 other protein kinases of di-
verse structural types, 11, including the mitotic kinases
CDK1 and PLK1, were inhibited with IC
 
50
 
 values 
 
 
 
10
 
 
 
M. Although MEK1 and SRC, which have been impli-
cated in mitotic progression, were inhibited in the 1 
 
 
 
M
range, the phenotypes described here are unlikely to be due
to inhibition of these enzymes because, in contrast to
ZM447439, selective SRC and MEK1 inhibitors delay
G2/M progression (Moasser et al., 1999; Wright et al.,
1999). Insight into the mechanism underlying the selectivity
of ZM447439 comes from the crystal structure of Aurora A
complexed with a related inhibitor (Andrew Pannifer and
Richard Pauptit, AstraZeneca Pharmaceuticals, personal
communication). This shows that the inhibitor occupies the
ATP binding pocket and an adjacent cleft that is not present
in other kinases. The sequence homology between the Au-
rora kinases (Bischoff and Plowman, 1999) suggests that
ZM447439 probably inhibits Aurora B, and possibly Aurora
C, in a similar manner. Although we cannot rule out the
possibility that ZM447439 inhibits other protein kinases
not tested, the RNAi data (Fig. 8) provide compelling evi-
dence that the phenotypes described here are due to inhibi-
tion of Aurora B, not Aurora A or any other protein kinase.
Aurora A is required for bipolar spindle formation in 
 
Dro-
Figure 8. Repression of Aurora B prevents kinetochore localization of BubR1. HeLa and DLD-1 cells were transfected with siRNA duplexes 
to repress either Aurora A or B. (A) Immunoblots of HeLa cell lysates showing repression of Aurora A and B. (B) Transfected DLD-1 cells were 
exposed to spindle toxins, and the mitotic index was measured over time. Values represent the mean and SEM from three independent experiments 
in which at least 1,000 cells were counted. (C) Projected deconvolved image stacks of nocodazole-treated mitotic DLD-1 cells after transfection 
of siRNAs targeting Aurora A (top) and Aurora B (bottom). (D) Examples of spindle morphology in control and Aurora B RNAi cultures. (E) Plot 
of interkinetochore distance in control and Aurora B–repressed cells.T
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sophila
 
 embryos and 
 
Xenopus
 
 egg extracts and centrosome
maturation in 
 
C. elegans
 
 embryos (Hannak et al., 2001). Al-
though we have not tested the effect of ZM447439 on cen-
trosome maturation, bipolar spindles do form in the pres-
ence of ZM447439. However, bipolar spindles also form
when Aurora A is repressed by RNAi (unpublished data),
suggesting that perhaps Aurora A is not required for spindle
bipolarity in human somatic cells.
 
Aurora B kinase activity regulates chromosome 
alignment and the spindle checkpoint
 
Consistent with previous reports (Adams et al., 2001c; Kal-
lio et al., 2002; Murata-Hori and Wang, 2002), our obser-
vations show that Aurora B is required for both spindle
checkpoint function and metaphase chromosome alignment
in human cells. By using a novel selective protein kinase in-
hibitor, we have been able to directly address, for the first
time, the requirement for Aurora B kinase activity in these
processes. Because the phenotypes derived from protein re-
pression and overexpression appear more extensive than
those induced by ZM447439, our data demonstrate the use-
fulness of small molecule inhibitors in dissecting complex
cellular processes. Indeed, kinetochore fibers form in the
presence of ZM447439, suggesting that Aurora B kinase ac-
tivity is not required for kinetochore–microtubule interac-
tions, but rather regulates these interactions to promote cor-
rect chromosome alignment. Such a role for Aurora B is
entirely consistent with the role Ipl1 plays in budding yeast:
Ipl1 is not required for the attachment of chromosomes to
the spindle, but rather resolves inappropriate kinetochore–
microtubule interactions to ensure correct bi-orientation
(Tanaka et al., 2002).
Ipl1 has also been implicated in spindle checkpoint func-
tion (Biggins and Murray, 2001) as well as chromosome
alignment. Because Aurora B also promotes chromosome
alignment, is it possible that its role in checkpoint activa-
tion is a secondary consequence of generating unattached
kinetochores, as has been argued for Ipl1 (Tanaka et al.,
2002)? If this were the case, we would predict that in the
absence of Aurora B kinase activity, BubR1 and Mad2
should localize to kinetochores that lack bound micro-
tubules. However, in the presence of nocodazole and
ZM447439, localization of both BubR1 and Mad2 to ki-
netochores is severely reduced. Thus, in human cells at
least, Aurora B kinase activity does appear to be directly re-
quired for checkpoint function.
The most striking observation in this work is the differen-
tial effect that ZM447439 has on nocodazole- and pacli-
taxel-induced mitotic arrest. Below, we consider two possi-
ble explanations for this observation, one of which is
qualitative in nature, the other quantitative. The “qualita-
tive” interpretation is that the checkpoint must be composed
of multiple pathways, one of which does not require Aurora
B kinase activity. If this is the case, then Aurora B kinase ac-
Figure 9. Repression of BubR1 prevents chromosome alignment. DLD-1 cells were transfected with siRNA duplexes to repress BubR1 and 
were then stained to detect Bub1 (green), tubulin (red), and DNA (blue). (A) Examples of abnormal prometaphase cells with chromosomes 
aligned along the length of the spindle rather than along the metaphase plate. Bar graph shows that  40% of prometaphases appear abnormal 
with chromosomes aligned along the length of the spindle. (B) Plot of interkinetochore distances measured using Bub1 foci to determine kinetochore 
position. (C) Proportion of mitotic cells exhibiting either prometaphase or metaphase chromosome alignment after a 1-h exposure to MG132. 
Values represent the mean and SEM derived from three independent experiments in which at least 100 mitotic cells were counted.T
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tivity is not essential for checkpoint activation in response to
loss of kinetochore–microtubule interactions and/or spindle
destruction, but is essential under conditions where kineto-
chores can capture microtubules, but not correctly align on
the spindle. This would indicate that, like Ipl1 in budding
yeast (Biggins and Murray, 2001), Aurora B does not di-
rectly monitor kinetochore–microtubule interactions, but
rather activates the checkpoint in response to loss of tension
at centromeres.
An alternative “quantitative” explanation is that Aurora B
simply targets BubR1 and Mad2 to kinetochores irrespective
of tension. Although ZM447439 clearly reduces kineto-
chore-associated BubR1 and Mad2 (by 
 
 
 
90 and 
 
 
 
70%, re-
spectively), perhaps the residual bound protein is sufficient
to sustain mitotic arrest in the absence of kinetochore–
microtubule interactions. If microtubule occupancy is suffi-
cient to then inactivate the remaining bound protein, this
may explain why cells cannot arrest in the presence of
ZM447439 and paclitaxel. Interestingly, kinetochore-bound
Cenp-E is almost twofold higher in cells treated with
ZM447439 and nocodazole compared with cells treated
with ZM447439 plus paclitaxel. Because Cenp-E is thought
to activate the checkpoint via BubR1 (Chan et al., 1999;
Yao et al., 2000), perhaps this elevated level of Cenp-E is
sufficient to activate the residual BubR1 and thus maintain
mitotic arrest in the presence of nocodazole.
At present, it is difficult to imagine how one could dis-
tinguish between these two possibilities. Indeed, whether
the spindle checkpoint monitors tension, microtubule at-
tachment, or both remains unsolved (Musacchio and
Hardwick, 2002). Although evidence from budding yeast
suggests that Ipl1 does activate the checkpoint in response
to the lack of tension (Biggins and Murray, 2001), there is
compelling evidence to argue that the checkpoint in mam-
malian somatic cells only monitors microtubule attach-
ment (Rieder et al., 1995). Yet mammalian kinetochores
are clearly sensitive to changes in tension (Waters et al.,
1998), and in particular BubR1, but not Mad2, is recruited
to aligned kinetochores after loss of tension (Skoufias et al.,
2001; Shannon et al., 2002). However, it is possible that
tension and attachment are not separable events in terms of
checkpoint function. Indeed, it was shown many years ago
that tension stabilizes microtubule attachment (Nicklas
and Koch, 1969). Furthermore, our observation showing
that BubR1 plays a dual role in congression and checkpoint
function indicates that the mechanisms which regulate and
monitor chromosome alignment are interweaved at the
molecular level.
 
Aurora inhibitors as potential therapeutic agents
 
The Auroras represent a new family of protein kinases with
oncogenic potential (Bischoff et al., 1998; Tatsuka et al.,
1998; Zhou et al., 1998; Adams et al., 2001a). Our observa-
tions show that it is possible to selectively inhibit Aurora ki-
nase activity in cells with a small molecule inhibitor. Fur-
thermore, we have shown that relative to cells with a
functional p53 response, p53-deficient cells are more likely
to continue cell cycle progression in the presence of
ZM447439. In addition, cycling cells rapidly lose viability
 
in the presence of ZM447439, whereas nondividing cells re-
tain viability. Together, these observations suggest that Au-
rora kinase inhibitors may be selectively toxic to proliferat-
ing tumor cells, and therefore open up new opportunities to
develop novel anti-cancer agents.
 
Materials and methods
 
In vitro kinase assays
 
Recombinant Aurora A and B were expressed as NH
 
2
 
-terminal His
 
6
 
-
tagged fusion proteins using a baculovirus expression system (FastBac™;
GIBCO BRL) according to the manufacturer’s instructions. Aurora A was
purified by affinity chromatography using Ni-NTA agarose, and Aurora B
was purified by ion exchange chromatography using CM Sepharose Fast
Flow (Amersham Biosciences). 1 ng purified recombinant enzyme was
added to a reaction cocktail containing 25 mM Tris-HCl, pH 7.5, 12.5
mM KCl, 2.5 mM NaF, 0.6 mM DTT, 6.25 mM MnCl
 
2,
 
 10 
 
 
 
M peptide
substrate (Biotinyl-Ahx-tetra (LRRWSLG); Bachem), 10 
 
 
 
M for Aurora A or
5 
 
 
 
M ATP for Aurora B, and 0.2 
 
 Ci  [
33P]ATP (specific activity  2,500
Ci/mmol; Amersham Biosciences), and was then incubated at RT for 60
min. Reactions were stopped by addition of 20% phosphoric acid, and
the products were captured on P30 nitrocellulose filters (Whatman) and
assayed for incorporation of 
33P with a Betaplate™ counter (Wallac). No
enzyme and no compound control values were used to determine the
concentration of ZM447439, which gave 50% inhibition of enzyme activ-
ity. Further details are available on request from Nicholas Keen (AstraZen-
eca Pharmaceuticals, Cheshire, UK).
Cell culture
A549, MCF-7, and DLD-1 cells (American Type Culture Collection), TA-
HeLa cells (Taylor and McKeon, 1997), U2OS cells stably transfected with
pCMVp53 143A, and parental U2OS cells (both from Karen Vousden,
Beatson Institute for Cancer Research, Glasgow, UK) were all cultured as
described previously (Taylor et al., 2001). Nontransformed human mam-
mary epithelial cells expressing hTERT (CLONTECH Laboratories, Inc.)
were cultured in MEGM (Clonetics). Nocodazole, paclitaxel, and thymi-
dine were used as described previously (Taylor et al., 2001). MG132 (Cal-
biochem) was dissolved in DMSO and used at a final concentration of 20
 M. ZM447439 was dissolved in DMSO at 10 mM and stored at  20 C
for up to 9 mo in individual aliquots to avoid freeze-thaw cycles, and was
then freshly diluted in media. The IC50 values for Aurora A and B ( 100
nM) were determined at the Km for ATP (see above). However, because
the cellular ATP concentration is  200-fold higher, and because
ZM447439 is an ATP competitor, we used ZM447439 at a concentration
of 2  M in all the cell assays unless stated otherwise. DMSO was added to
drug-free cultures to account for the solvent.
Cell cycle analysis and cloning assays
DNA content and mitotic index measurements and synchronization of TA-
HeLa cells at G1/S using a double thymidine block were done as described
previously (Taylor and McKeon, 1997). To determine cloning efficiency,
MCF7 cells were plated in phenol red free DME plus 5% stripped serum
(HyClone), and were then treated with or without the anti-estrogen ICI
182780 at 1  M for 48 h. ZM447439 was then added at the indicated con-
centrations for 72 h. The cells were harvested, washed, and  400 cells
plated in each well of a 6-well plate in complete media without
ZM447439. After 10 d, the colonies were fixed, stained with crystal violet,
and counted. The cloning efficiency represents the number of colonies on
ZM447439-treated plates compared with DMSO-treated controls.
Antibody techniques
Immunofluorescence, immunoblotting, and immunoprecipitations were all
done as described previously (Taylor et al., 2001) using antibodies against
the following: phosphohistone H3 (Upstate Biotechnology); cyclin B1 (Up-
state Biotechnology); tubulin (TAT1); centromere/kinetochores (human
ACA); BubR1 (SBR1.1); Bub1 (4B12); Aurora A (RAA.1); and Myc-tag
(9E10). Aurora B was detected using either the anti-AIM-1 mouse mAb
(Transduction Laboratories) or a sheep anti–human Aurora B pAb (unpub-
lished data). For localization of Mad2 and Survivin, we used DLD-1 cell
lines stably expressing Myc-tagged hMad2 or hSurvivin ORFs (unpub-
lished data). For IP kinase assays, beads were equilibrated in kinase buffer
(10 mM Tris, pH7.5, 5 mM KCl, 1 mM NaF, 0.24 mM DTT, and 2.5 mM
MnCl) and were then incubated at RT for 1 h in kinase buffer supple-T
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mented with 2.5  M ATP, 5  Ci  [
32P]ATP, and 3  M biotinyl-Ahx-tetra
(LRRWSLG) peptide substrate. Reactions were stopped with 20% phos-
phoric acid, and were then spotted onto P30 filtermat (Whatman). After
five washes in 0.5% phosphoric acid, bound radiolabel was quantitated by
scintillation counting. Deconvolution microscopy and pixel intensity
quantitation were performed as described previously (Taylor et al., 2001).
In brief, kinetochore fluorescence values were determined using softWoRx
imaging software (Applied Precision). Background readings were sub-
tracted, and the values were then normalized against the ACA signal to ac-
count for any variations in staining or image acquisition. SoftWoRx was
used to measure interkinetochore distances using either ACA or Bub1 foci
as indicated to determine kinetochore position.
Electron microscopy
Cells were fixed with 2.5% glutaraldehyde in phosphate buffer for 2 h at
RT, and were then pelleted and post-fixed in 1% osmium tetroxide for 1 h
at RT. After washes, samples were stained en bloc in 1% uranyl acetate for
16 h at 4 C, dehydrated with acetone, and then embedded in Spurr’s resin.
70-nm sections were cut, stained with uranyl acetate and lead citrate, then
examined on an electron microscope (Tecnai 12 BioTWIN; FEI Company).
RNAi
siRNA duplexes (Dharmacon Research) designed to repress Aurora A (5 -
AAGCACAAAAGCUUGUCUCCA-3 ), Aurora B (5 -AACGCGGCACUU-
CACAAUUGA-3 ), and BubR1 (5 -AACGGGCAUUUGAAUAUGAAA-3 )
were transfected using OligofectAMINE™ (Invitrogen) according to the
manufacturer’s instructions. In brief, 10
5 cells were seeded in wells of a
24-well plate 24 h before transfection. siRNA duplexes and Oligo-
fectAMINE™ were diluted in media, mixed, and incubated for 20 min.
siRNA/lipid complexes were then added to cells for 4 h followed by addi-
tion of complete media. 24 h later, the cells were replated and then ana-
lyzed 48–72 h after transfection.
Transient transfections
The human Aurora B ORF (Bischoff et al., 1998) was amplified by PCR,
cloned into pcDNA-3 Myc (Taylor and McKeon, 1997), mutated to create
K106R, and sequenced, all after standard procedures. Plasmid DNA was
then transfected into TA-HeLa cells on coverslips using the ProFection
®
calcium phosphate kit (Promega). 24 h after transfection, the cells were
fixed with 1% formaldehyde in PBS and processed for immunofluores-
cence as described above.
Online supplemental material
The supplemental figures and tables show (1) the effects of ZM447439 and
Aurora B RNAi on Cenp-E and Mad2 localization; (2) the effect of BubR1
RNAi on the spindle checkpoint; and (3) quantitation of the data from the
experiment examining the effect of ZM447439 on interkinetochore dis-
tance and BubR1 binding. Online supplemental material available at http://
www.jcb.org/cgi/content/full/jcb.200208091/DC1
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